Evidence map›Paper›PMID 26156326›Full record

ArticleThe oncologist2015

Next-Generation Sequencing and Immunohistochemistry as Future Gold Standard of ALK Testing in Lung Cancer?

Arnaud Uguen, Matthieu Talagas, Pascale Marcorelles, Paul Guéguen, Sebastian Costa, Sophie Andrieu-Key, Marc De Braekeleer

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. In Reply.The oncologist · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Arnaud UguenINSERM, U1078, Brest, France; Centre Hospitalier Régional et Universitaire (CHRU) Brest, Service d'Anatomie et Cytologie Pathologiques, Brest, France; Université Européenne de Bretagne, Rennes, France.
Matthieu TalagasCHRU Brest, Service d'Anatomie et Cytologie Pathologiques, Brest, France; Université Européenne de Bretagne, Rennes, France; Faculté de Médecine et des Sciences de la Santé Université de Brest, Brest, France.
Pascale MarcorellesCHRU Brest, Service d'Anatomie et Cytologie Pathologiques, Brest, France; Université Européenne de Bretagne, Rennes, France; Faculté de Médecine et des Sciences de la Santé Université de Brest, Brest, France.
Paul GuéguenINSERM, U1078, Brest, France ; Université Européenne de Bretagne, Rennes, France; CHRU Brest, Laboratoire de Génétique Moléculaire et d'Histocompatibilité, Brest, France.
Sebastian CostaCHRU Brest, Service d'Anatomie et Cytologie Pathologiques, Brest, France.
Sophie Andrieu-KeyCHRU Brest, Service d'Anatomie et Cytologie Pathologiques, Brest, France.
Marc De BraekeleerINSERM, U1078, Brest, France; Université Européenne de Bretagne, Rennes, France; CHRU Brest, Laboratoire de Cytogénétique et Biologie de la Reproduction, Brest, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene RearrangementAdenocarcinomaFemaleHumansLung NeoplasmsMaleMass ScreeningOncogene Proteins, FusionOncogene Proteins, Fusion

Identifiers

PMID26156326
PMCPMC4524757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.